Citations

Showing 10 of 108083 citations.

Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis
Tefferi, Ayalew , Mudireddy, Mythri , Gangat, Naseema , Hanson, Curtis A. , Ketterling, Rhett P. , Pardanani, Animesh , Nagorney, David M. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | August 7, 2017 | Volume: 92 | Issue: 11 | Pages: 1187-1192

10.1002/ajh.24881 | PMID 28782256 Get It

AbstractPalliative treatment in myelofibrosis (MF) includes transfusion support, JAK2 inhibitors, involved field radiotherapy and splenectomy. To assist in selecting patients who are likely to benefit from splenectomy, we looked into risk factors for postsplenectomy survival, in 120 consecutive cases (median age 66 years); at the time of splenectomy, 61% displayed red cell transfusion need, 49% platelet count <100 × 10(9)/L, 25% leukocyte count >25 × 10(9)/L, 60% constitutional symptoms and 13% circulating blasts ≥5%; dynamic international prognostic scoring system risk categories were 21% high, 55% intermediate‐2, 21% intermediate‐1 and 3% low. Among informative cases, karyotype was abnormal in 60% and driver mutational status was JAK2 75%, CALR 15%, MPL 4% and triple‐negative 6%. At median follow‐up of 1.3 years, from time of splenectomy, 95 (79%) deaths and 30 (25%) leukemic transformations were recorded. Median postsplenectomy survival was 1.5 years; in multivariable analysis, survival was adversely affected by age >65 years, transfusion need, leukocyte count >25 × 10(9)/L and circulating blasts ≥5%; these variables were subsequently used to devise an HR‐weighted scoring system with high (3‐4 risk factors), intermediate (2 risk factors) and low (0‐1 risk factors) risk categories; the corresponding postsplenectomy median survivals were 0.3 (HR 5.9, 95% CI 3.2‐11.0), 1.3 (HR 2.9, 95% CI 1.8‐4.6) and 2.9 years. Postsplenectomy survival was not affected by driver mutational status or occurrence of leukemic transformation. Leukemia‐free survival was predicted by very high risk karyotype. The observations from the current study might help identify appropriate candidates for splenectomy in MF.
Lateral Meniscus Allograft Transplantation: The Bone Plug Technique
Johnson, Nick R., Levy, Bruce A. , Krych, Aaron J. , Woodmass, Jarret M, Krych, Aaron J , Woodmass, Jarret Murray , Stuart, Michael J.

Mayo Clinic

Arthroscopy Techniques | August 7, 2017 | Volume: 6 | Issue: 4 | Pages: No page available

10.1016/j.eats.2017.04.016 | PMID 29354420 Get It

Abstract Lateral meniscus tears are commonly encountered by orthopaedic surgeons. Despite efforts to repair and preserve the meniscus, meniscectomy is occasionally required to treat irreparable tears. The resulting lateral meniscus deficiency leads to increased tibiofemoral contact pressures and ultimately early osteoarthritic changes in the knee. Lateral meniscal allograft transplant (LMAT) has been proposed as a way to restore the lateral meniscus–deficient knee to its native form. Although several techniques for LMAT have been proposed, osseous fixation has demonstrated increased stability, improved outcomes, and improved long‐term survival. This article presents a technique for LMAT using bone plugs and standard arthroscopic portals. Technique Video video See video under supplementary data.
The future burden of Parkinson's disease
Rocca, Walter A.

Mayo Clinic

Movement Disorders | August 7, 2017 | Volume: 33 | Issue: 1 | Pages: 8-9

10.1002/mds.27114 | PMID 28782890 Get It

The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease
Saffouri, George, Loftus, Edward V. , Pardi, Darrell S. , Khanna, Sahil , Loftus, Edward V , Gupta, Arjun , Baddour, Larry M.

Mayo Clinic

Scandinavian Journal of Gastroenterology | August 7, 2017 | Volume: 52 | Issue: 11 | Pages: 1240-1247

10.1080/00365521.2017.1362466 | PMID 28782372 Get It

Liver transplantation: Rejection and tolerance
Taner, Timuçin

Mayo Clinic

Liver Transplantation | August 5, 2017 | Volume: 23 | Issue: S1 | Pages: S85-S88

10.1002/lt.24840 | PMID 28779559 Get It

Very high‐frequency oscillations: Novel biomarkers of the epileptogenic zone
Brázdil, Milan , Pail, Martin , Halámek, Josef , Plešinger, Filip , Cimbálník, Jan , Román, Róbert , Klimeš, Petr , Daniel, Pavel, Chrastina, Jan , Rektor, Ivan , Jurák, Pavel , Brazdil, Milan , Brichtová, Eva , Worrell, Gregory A. , Klimes, Petr , Daniel, Pavel , Roman, Robert

Mayo Clinic

Annals of Neurology | August 5, 2017 | Volume: 82 | Issue: 2 | Pages: 299-310

10.1002/ana.25006 | PMID 28779553 Get It

ObjectiveIn the present study, we aimed to investigate depth electroencephalographic (EEG) recordings in a large cohort of patients with drug‐resistant epilepsy and to focus on interictal very high‐frequency oscillations (VHFOs) between 500Hz and 2kHz. We hypothesized that interictal VHFOs are more specific biomarkers for epileptogenic zone compared to traditional HFOs.MethodsForty patients with focal epilepsy who underwent presurgical stereo‐EEG (SEEG) were included in the study. SEEG data were recorded with a sampling rate of 25kHz, and a 30‐minute resting period was analyzed for each patient. Ten patients met selected criteria for analyses of correlations with surgical outcome: detection of interictal ripples (Rs), fast ripples (FRs), and VHFOs; resective surgery; and at least 1 year of postoperative follow‐up. Using power envelope computation and visual inspection of power distribution matrixes, electrode contacts with HFOs and VHFOs were detected and analyzed.ResultsInterictal very fast ripples (VFRs; 500–1,000Hz) were detected in 23 of 40 patients and ultrafast ripples (UFRs; 1,000–2,000Hz) in almost half of investigated subjects (n = 19). VFRs and UFRs were observed only in patients with temporal lobe epilepsy and were recorded exclusively from mesiotemporal structures. The UFRs were more spatially restricted in the brain than lower‐frequency HFOs. When compared to R oscillations, significantly better outcomes were observed in patients with a higher percentage of removed contacts containing FRs, VFRs, and UFRs.InterpretationInterictal VHFOs are relatively frequent abnormal phenomena in patients with epilepsy, and appear to be more specific biomarkers for epileptogenic zone when compared to traditional HFOs. Ann Neurol 2017;82:299–310
Effect of Disclosing Genetic Risk for Coronary Heart Disease on Information Seeking and Sharing
Brown, Sherry‐Ann , Jouni, Hayan, Marroush, Tariq S. , Brown, Sherry-Ann N, Kullo, Iftikhar J.

Mayo Clinic

Circulation: Cardiovascular Genetics | August 5, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circgenetics.116.001613 | PMID 28779015 Get It

Background— Whether disclosing genetic risk for coronary heart disease (CHD) to individuals influences information seeking and information sharing is not known. We hypothesized that disclosing genetic risk for CHD to individuals influences information seeking and sharing. Methods and Results— The MI-GENES study (Myocardial Infarction Genes) randomized participants (n=203) aged 45 to 65 years who were at intermediate CHD risk based on conventional risk factors and not on statins to receive their conventional risk score alone or also a genetic risk score based on 28 variants. CHD risk was disclosed by a genetic counselor and then discussed with a physician. Surveys assessing information seeking were completed before and after risk disclosure. Information sharing was assessed post-disclosure. Six-month post-disclosure, genetic risk score participants were more likely than conventional risk score participants to visit a website to learn about CHD (odds ratio [OR], 4.88 [confidence interval (CI), 1.55–19.13]; P =0.01), use the internet for information about how genetic factors affect CHD risk (OR, 2.11 [CI, 1.03–4.47]; P =0.04), access their CHD risk via a patient portal (OR, 2.99 [CI, 1.35–7.04]; P =0.01), and discuss their CHD risk with others (OR, 3.13 [CI, 1.41–7.47]; P =0.01), particularly their siblings (OR, 1.92 [CI, 1.06–3.51]; P =0.03), extended family (OR, 3.8 [CI, 1.37–12.38]; P= 0.01), coworkers (OR, 2.42 [CI, 1.09–5.76]; P =0.03), and primary care provider (PCP; OR, 2.00 [CI, 1.08–3.75]; P =0.03). Conclusions— Disclosure of a genetic risk score for CHD increased information seeking and sharing. Clinical Trial Registration— URL: https://clinicaltrials.gov/ . Unique identifier: NCT01936675.
A Commensal Bifidobacterium longum Strain Prevents Gluten-Related Immunopathology in Mice through Expression of a Serine Protease Inhibitor
McCarville, Justin L. , Dong, Jasmine, Caminero, Alberto , Jury, Jennifer , Duboux, Stéphane , Delley, Michelle, Tangyu, M., Mercenier, Annick , Bergonzelli, Gabriela E. , Verdú, Elena F. , Verdu, Elena F , Bermúdez-Brito, Miriam , Murray, Joseph A. , Steinmann, Maren , Langella, Philippe , Caminero, A

Mayo Clinic

Applied and Environmental Microbiology | August 5, 2017 | Volume: 83 | Issue: 19 | Pages: No page available

10.1128/aem.01323-17 | PMID 28778891 Get It

ABSTRACT Microbiota-modulating strategies, including probiotic administration, have been tested for the treatment of chronic gastrointestinal diseases despite limited information regarding their mechanisms of action. We previously demonstrated that patients with active celiac disease have decreased duodenal expression of elafin, a human serine protease inhibitor, and supplementation of elafin by a recombinant Lactococcus lactis strain prevents gliadin-induced immunopathology in the NOD/DQ8 mouse model of gluten sensitivity. The commensal probiotic strain Bifidobacterium longum NCC2705 produces a serine protease inhibitor (Srp) that exhibits immune-modulating properties. Here, we demonstrate that B. longum NCC2705, but not a srp knockout mutant, attenuates gliadin-induced immunopathology and impacts intestinal microbial composition in NOD/DQ8 mice. Our results highlight the beneficial effects of a serine protease inhibitor produced by commensal B. longum strains. IMPORTANCE Probiotic therapies have been widely used to treat gastrointestinal disorders with variable success and poor mechanistic insight. Delivery of specific anti-inflammatory molecules has been limited to the use of genetically modified organisms, which has raised some public and regulatory concerns. By examining a specific microbial product naturally expressed by a commensal bacterial strain, we provide insight into a mechanistic basis for the use of B. longum NCC2705 to help treat gluten-related disorders.
Muscle strengthening method using electrical stimulation on antagonist muscle
Nishimura, Hisanori, Imaishi, Kisei, Iwasa, Kiyohiko, Hirota, Keisuke , Tagawa, Yoshihiko, Yamamoto, Toshiyasu, Basford, Jeffrey R.

Mayo Clinic

The proceedings of the JSME annual meeting | August 4, 2017 | Volume: 2000.1 | Pages: 363-364

10.1299/jsmemecjo.2000.1.0_363 Get It

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Alberts, Rudi , Vries, Elisabeth M. G. de, Goode, Elizabeth C. , Jiang, Xiaojun , Sampaziotis, Fotis , Rombouts, Krista , Böttcher, Katrin , Folseraas, Trine , Weismüller, Tobias J. , Alexander, Graeme, Alvaro, Domenico , Bergquist, Annika , Björkström, Niklas K. , Beuers, Ulrich , Boberg, Kirsten Muri , Bowlus, Christopher L. , Bragazzi, Maria Consiglia , Chazouillères, Olivier , Cheung, Angela , Dalekos, Georgios, Eaton, John E. , Eksteen, Bertus , Ellinghaus, David , Färkkilâ, Martti , Festen, Eleonora A. , Floreani, Annarosa , Franceschet, I., Gotthardt, Daniel , Hoek, Bart van , Holm, Kristian , Hov, Johannes R. , Imhann, Floris , Juran, Brian D., Lenzen, Henrike , Marschall, Hanns–Ulrich , Marzioni, Marco , Melum, Espen , Milkiewicz, Piotr , Müller, Tobias , Parés, Albert , Rupp, Christian , Rust, Christian, Sandford, Richard , Schrumpf, Erik, Silverberg, Mark S. , Srivastava, Brijesh, Sterneck, Martina , Teufel, Andreas , Vallier, Ludovic , Verheij, Joanne , Vila, Arnau Vich , Vries, Boudewijn de, Zachou, Kalliopi , Chapman, Roger W. , Manns, Michael P. , Rushbrook, Simon, Anderson, Carl A. , Karlsen, Tom H. , Ponsioen, Cyriel Y. , Weersma, Rinse K. , Eaton, John, Lazaridis, Konstantinos N. , Ellinghaus, David , Bowlus, Christopher L , Marzioni, Marco , Mason, Andrew L. , Wang, Weiwei , Bjornsson, Einar Stefan , Carbone, Marco , Dalekos, Georgios, Hirschfield, Gideon M. , Hohenester, Simon D. , Invernizzi, Pietro , Lieb, Wolfgang , Liu, Jimmy Z. , Schramm, Christoph , Schreiber, Stefan , Pinzani, Massimo , Franke, André , Bergquist, Annika , Milkiewicz, Piotr , Alvaro, Domenico , Hov, Johannes R , Anderson, Carl A

Mayo Clinic

Gut | August 4, 2017 | Volume: 67 | Issue: 8 | Pages: 1517-1524

10.1136/gutjnl-2016-313598 | PMID 28779025 Get It

Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications. Design We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes. Results We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07×10–9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells. Conclusion We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene.